Cempra (CEMP) Added to Focus List at Roth Capital

Roth Capital analyst Debjit Chattopadhyay added Cempra, Inc. (NASDAQ: CEMP) to its Focus List. The firm maintained a Buy rating and price target of $42.

Chattopadhyay commented, "Based on the robust readout from the Solitaire Oral study, expectations have ratcheted higher heading into the IV data (expected during 4Q). A statistically-significant benefit (older, sicker patients) could be a big win, with positive ramifications for pricing and adoption especially in the hospital setting, in our view. Solithromycin (pediatric, COPD, gonorrhea, NASH) or Taksta (ABSSI, B&J infections) are compelling opportunities and not reflected in the stock, in our opinion."

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Shares of Cempra, Inc. closed at $36.14 yesterday.

You May Also Be Interested In

• Seaport Global Securities Downgrades MSG Entertainment (MSGE) to Neutral
• Warner Brothers Discovery (WBD) Reiterated at Hold by Benchmark on Supergirl Opening
• UBS Reiterates Buy Rating on Williams Companies (WMB)